Dual Function Injectable Hydrogel for Controlled Release of Antibiotic

Subscriber access provided by University of Texas Libraries

Article

Dual Function Injectable Hydrogel for Controlled Release of Antibiotic and Local Antibacterial Therapy Jiaul Hoque, Brinta Bhattacharjee, Relekar G. Prakash, Krishnamoorthy Paramanandham, and Jayanta Haldar Biomacromolecules, Just Accepted Manuscript • DOI: 10.1021/acs.biomac.7b00979 • Publication Date (Web): 28 Aug 2017 Downloaded from http://pubs.acs.org on August 29, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Biomacromolecules is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Dual Function Injectable Hydrogel for Controlled Release of Antibiotic and Local Antibacterial Therapy Jiaul Hoque†, Brinta Bhattacharjee†, Relekar G. Prakash†, Krishnamoorthy Paramanandham‡ and Jayanta Haldar†*

†

Antimicrobial Research Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for

Advanced Scientific Research, Jakkur, Bengaluru 560064, India. ‡

National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI),

Ramagondanahalli, Yelahanka, Bengaluru 560064, India

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Abstract. We present vancomycin-loaded dual-function injectable hydrogel that delivers antibiotic locally suitable for treatment of infections in avascular or necrotic tissues. The syringe-deliverable gels were developed using polydextran aldehyde and an inherently antibacterial polymer N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride along with vancomycin. The antibiotic was primarily encapsulated via reversible imine bonds formed between vancomycin and polydextran aldehyde in the hydrogel which allowed sustained release of vancomycin over an extended period of time in a pH dependent manner. Being inherently antibacterial, the gels displayed excellent efficacy against bacteria due to dual mode of action (killing bacteria upon contact as well as by releasing antibiotics into surroundings). Upon subcutaneous implantation, the gel was shown to kill methicillinresistant Staphylococcus aureus (>99.999%) when bacteria were introduced directly into the gel as well as at distal site from the gel in a mice model. These materials thus represent as novel non-invasive drug-delivery device suitable for local antibiotic therapy.

Keywords: Bioadhesive injectable hydrogel, local drug delivery, vancomycin, antibacterial activity, methicillin-resistant Staphylococcus aureus


Page 2 of 36

Page 3 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

1. Introduction Combating infections in relatively less vascular tissues (e.g., bone infections), in avascular tissues (e.g., cartilage infections) or in necrotic tissues (e.g., surgical site infections, SSI) are very challenging because of the limited penetration of antibiotics into the target sites.1-3 The risk further increases with the introduction of a medical device or implant due to the microbial biofilm formation on the easily colonisable surfaces of the device/implant.4 Generally, treatment of these infections is carried out via prolonged course of oral or intravenous antibiotics which require usage of the drugs from weeks to months. Despite systemic treatments, severe infections can emerge due to lack of effective amount of antibiotics at target site which, in extreme cases, can cause whole body infections known as sepsis.5,6 Furthermore, systemic delivery of antibiotics is limited due to higher propensity of bacterial resistance development and, with extensive and higher doses, can have lethal side effects.7,8 Thus there is a pressing need to develop potent delivery systems which not only would reduce the side effects but also increase efficacy of the drug by releasing it near the target site. Several release systems based on natural or synthetic polymers and hydrogels have been developed.9-15 These systems, acted as a drug-depot, were shown to achieve high local therapeutic concentration without much systemic distribution. However, the major drawback of these systems is the need of an invasive surgery required to implant them at the site of applications which often involves additional medical risks and complications such as increased cost, patient-sufferings and bacterial infections. Ideally a delivery system, if injectable, can be simply applied at the target site without an invasive surgical procedure.16-20 Towards this goal, bioadhesive injectable hydrogels offer several advantages as they not only would fix themselves locally by reacting with extracellular matrix (ECM) thus acting as tissue-adhesives but also would provide high-viscosity matrix for the controlled release of therapeutics locally.21-24


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Injectable hydrogels that cross-link in-situ and deliver antibacterial agents/antibiotics were developed and have been shown to be active against microbes.25-28 However, the matrixes of the gels are either non-antibacterial or poorly antibacterial. As a result, the gel systems primarily depend on the encapsulated antibacterial agents for their bioactivity. Another major problem of current delivery systems is the burst and rapid release of the antibacterial agents due to non-covalent encapsulation of the drug molecules into the matrix which limits their long-lasting antibacterial efficacy. In-situ forming hydrogels with innate antibacterial activity have also been developed and shown to possess promising bactericidal efficacy.29-32 However, these gels require direct bacterial contact to kill the pathogens. Further, these materials are not suitable for treating infections which might be at distal places far from the site of applications. An antibiotic-loaded bioadhesive injectable hydrogel with innate antibacterial activity should combat such infections more efficiently as these materials would not only act via dual mode of action (would kill bacteria upon contact as well as by releasing antibiotics into the surroundings) but also deliver antibiotics into the target site without much systemic distribution. Additionally being bioadhesive, these materials would fix themselves at the target site thereby would allow local and site-specific delivery. Moreover, encapsulation of the antibiotic via reversible covalent bond into the injectable matrix might provide gradual and slow release of the antibiotics for longer duration locally. Herein we present a highly efficient antibiotic-loaded dual-function injectable hydrogel capable of releasing the antibiotic in a controlled manner via reversible imine bonds between the antibiotic and the hydrogel. The antibiotic that was chosen for this study was one of the most efficient drugs, vancomycin. Vancomycin and its derivatives are known to be highly active against various Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and were used as the drug of last resort.33,34 The hydrogels were prepared using a bioadhesive polymer, polydextran aldehyde (PDA) and an inherently


Page 4 of 36

Page 5 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

antibacterial polymer, N-(2-hydroxy) propyl-3-trimethylammonium chitosan chloride (HTCC). Since vancomycin contains free primary amine group, it was either completely or partially reacted with the gel matrix through imine bond formation depending on the vancomycin/PDA ratio. The effect of vancomycin content on bactericidal efficacy of the gels was also systematically studied thus an optimum formulation suitable for in-vivo applications was obtained. Notably, antibiotic-loaded hydrogels showed much superior activity against bacteria than the gel without any antibiotic and displayed remarkably long-lasting activity. Further, gels were shown to release the antibiotic in a controlled and pH dependent manner. Moreover, the gel was shown to be significantly effective in killing MRSA when bacteria were injected not only into the gel but also at distal site (far from the gel) while being nontoxic and biocompatible to mammalian cells both in-vitro and in-vivo.

2. Experimental Section 2.1 Materials. Dextran from Leuconostic spp. (Mr ∼40 kDa), glycidyltrimethylammonium chloride (GTMAC), sodium periodate (NaIO4), hydroxyl amine, methyl orange and acetic acid were purchased from Sigma-Aldrich, USA and used as received. Chitosan with a degree of acetylation (DA) of ∼15% (molecular weight = 15 kDa) was purchased from Polysciences, USA. Ethanol, acetone, and other organic solvents were of analytical grade and purchased from Spectrochem, India. Staphylococcus aureus (MTCC 737) was purchased from MTCC (Chandigarh, India). Methicilin-resistant Staphylococcus aureus (MRSA) (ATCC 33591) was obtained from ATCC (Rockvillei, Md). Bacterial growth media and agar were provided by HIMEDIA, India. Nuclear magnetic resonance spectra (1H NMR and

13

C NMR) were

recorded on a Bruker AMX-400 instrument (400 MHz) in deuterated solvents. FT-IR spectra of the solid compounds were recorded on Bruker IFS66 V/s spectrometer using KBr pellets. Scanning electron microscopy images were captured in using field emission scanning


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

electron microscope (Quanta 3D FEG, FEI). Oscillatory rheology was performed on preformed hydrogels using a TA Instrument AR-G2 rheometer, with 25 mm diameter stainless steel parallel plate tool. Centrifugation was performed via Eppendorf 5810R centrifuge. Optical density was measured via TECAN (Infinite series, M200 pro) Plate Reader. Studies on animal subjects were performed following the protocols approved by Institutional Bio-safety Committee (IBSC) of Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR). Studies with the animals were performed following protocols approved by the Institutional Animal Ethics Committee (IAEC) in the institute (Jawaharlal Nehru Centre for Advanced Scientific Research).

2.2 Synthesis and characterization of the hydrogels. Vancomycin was dissolved in phosphate buffer (23.5 mM NaH2PO4, 80.5 mM Na2HPO4) at different amounts (1 mg/mL, 6 mg/mL and 12 mg/mL). To this PDA was added to obtain PDA solution (50 mg/mL) containing vancomycin in the above mentioned concentration (5 wt% PDA, 0.1 wt%, 0.6 wt% and 1.2 wt% vancomycin respectively). After 1 h, an equal volume of 40 mg/mL HTCC (4.0 wt%) dissolved in Millipore water was added to the vancomycin-containing PDA solution. The mixture was then kept in an incubator for 15 min at 37 ˚C to allow gel formation. This resulted in various gel formulations (IHV-1: 2.5 wt% PDA with 0.05 wt% vancomycin and 2.0 wt% HTCC; IHV-2: 2.5 wt% PDA with 0.3 wt% vancomycin and 2.0 wt% HTCC; IHV-3: 2.5 wt% PDA with 0.6 wt% vancomycin and 2.0 wt% HTCC). Hydrogel without any vancomycin (IHV-0) was prepared by adding 5 wt% PDA solution to 4 wt% HTCC solution. The gels were prepared directly in the wells of a 96-well plate or in a sample vial or in petri dish either by simple mixing of the solutions or by mixing via dual barrel syringe. The gels were characterized via Fourier transform infrared spectroscopy (FTIR),


Page 6 of 36

Page 7 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

field emission scanning electron microscope (FESEM) and oscillatory rheology. The details of the characterization were provided in the Supporting Information.

2.3 Determination of vancomycin conjugation. The extent of covalent conjugation of vancomycin to PDA and hence in the gel was determined as follows: PDA and vancomycin mixture (PDA at 50 mg/mL and vancomycin at 1 mg/mL or 6 mg/mL or 12 mg/mL) in phosphate buffer (5 mL) and kept at 37 ˚C for 1 h in the dark. The solution was then dialyzed for 6-8 h using dialysis membranes (molecular cut off 3500 kDa) at 4 ˚C in deionized water in the dark by changing water on a regular interval with 30 min between each water change. The solution was then freeze dried and stored at 4 ˚C under dark condition. 1H-NMR and FTIR spectra of the freeze dried sample were then recorded in deuterioted solvent and KBr pellets respectively. The freeze dried samples were also used for elemental analyses after drying in a vacuum over at 55 ˚C.

2.4 In-vitro antibacterial activity of the hydrogel. First the hydrogels with or without antibiotic were prepared in the wells of a 96-well plate (50 µL 50 mg/mL of PDA containing 1 mg/mL or 6 mg/mL or 12 mg/mL of vancomycin and 50 µL 40 mg/mL of HTCC). The plate was then kept for 10-15 min in an incubator to allow the gel formation. To the wells bacteria (150 µL of ∼105 CFU/mL or 107 CFU/mL of S. aureus and MRSA) were added. The plates containing bacteria were then incubated at 37 ˚C for about 6 h under constant shaking. After incubation, 50 µL of bacterial suspension was either directly plated or diluted following 10-fold serial dilution and then plated on suitable agar plate. The agar plates were then incubated for about 24 h at 37 ˚C. Finally bacterial colonies were counted to evaluate the reduction in viable cells. The presence of viable bacterial count in each case was then


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

expressed as log CFU/mL. A similar experiment was performed with the blank wells without any gels and hydrogel without any vancomycin as controls.

2.5 Diffusion of antibiotic (zone of inhibition). Nutrient agar gels were prepared in petri dishes (90 mm) according to the manufacturer’s protocols. Briefly, 2.5 g of nutrient agar was dissolved in 100 mL of Millipore water and then autoclaved for 15-18 min at 121 ˚C. After cooling to 50 ˚C, a volume of 12-15 mL of the agar solution was added to the petri dishes and allowed to cool to room temperature, resulting in solid agar gel. A circular piece (6 mm in diameter) of the agar gel was removed by incision to reveal the underlying polystyrene. A 50 µL of IHV-0, IHV-1, IHV-2 and IHV-3 gel was then prepared in the cavity of agar plates following the method as mentioned previously. The hydrogel was incubated at 37 ˚C for 15 min, after which the gel surfaces were washed three times with 5 mL of PBS to remove any non-cross-linked HTCC and to ensure that the pH was equilibrated. A volume of 1 mL ml of 108 CFU/mL of S. aureus and MRSA was added to each dish and gently rocked to provide the full surface coverage. The plates were then incubated for 24 h imaged by Cell biosciences gel documentation instrument.

2.6 Released-based activity. Hydrogels (400 µL) were prepared in the inserts of a trans-well cell culture plate (24-well). The surfaces of the gels were washed by PBS (1 mL) to the bottom of the wells in the 24-well plate. PBS (100 µL) was added onto the surface of the gel. The plates were then kept for 15 min in an incubator set at 37 ˚C and the PBS solutions from the bottom and top of the gels were removed. Similarly, the gels were further washed two more times. Bacteria (500 µL, ∼104 CFU/mL of S. aureus and MRSA) were added to the bottom of the wells of trans-well cell culture plate and then the inserts containing the hydrogels were placed above the bacterial suspension. Nutrient media without bacteria (100


Page 8 of 36

Page 9 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

µL) was also added onto the surface of the hydrogel. A control was made where only bacteria (500 µL, ∼104 CFU/mL of S. aureus and MRSA) were incubated. Then the well plate was incubated at 37 ˚C for about 24 h. Finally, bacterial growth was determined by measuring the OD values of the bacterial suspension. Cell viability was then calculated with respect to the OD values of the control wells and taking it as 100% bacterial growth.

2.7 In-vitro release kinetics of vancomycin from the gels. Hydrogels (IHV-1, IHV-2 and IHV-3) were prepared in eppendorf tube (2 mL) in a similar way as described previously (200 µL of 50 mg/mL PDA with 1, 6 and 12 mg/mL vancomycin and 200 µL of 40 mg/mL HTCC). After the preparation, 1 mL of phosphate buffer of varying pH (5.5, 6.2 and 7.2) was added on top of the gel. Then the gel with added buffer was kept for constant shaking at 37 °C for 24 h. After 24 h, the buffer was collected and replaced with the fresh buffer. The process was repeated for 14 days. Finally, the amount of released vancomycin was determined by UV-visible absorption spectroscopy. A standard calibration curve of absorption intensity versus concentration was generated for vancomycin (absorbance at 281 nm). The concentration of the released vancomycin was then determined after measuring the absorbance and fixing the value in the absorption intensity versus concentration curve.

2.8 Long lasting antibacterial activity. Hydrogel (IHV-2) was prepared in eppendorf tube (2 mL) by mixing the components (200 µL of 50 mg/mL PDA with 6 mg/mL vancomycin and 200 µL of 40 mg/mL HTCC). After the preparation, 1 mL of PBS buffer or nutrient media was added on top of the gel. Then the gel with the added liquids was kept for constant shaking at 37 °C for 24 h. After 24 h, the buffer or media was collected and replaced with the fresh buffer. The process was repeated for next 14 days. Finally, the antibacterial activity of the released vancomycin was determined by taking 450 µL of the buffer or media with 50 µL


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

of ~107 CFU/mL MRSA. The bacterial mixture was kept for 24 h and then OD value was recorded. Also, the released media-bacterial solution was directly spot plated on agar plate to determine the bactericidal effect of the released vancomycin.

2.9 Hemolytic activity. Toxicity of the gels towards human red blood cells (hRBC) in-vitro was evaluated by exposing the gel surface with hRBC. The details of the procedure were provided in the Supporting Information.

2.10 In-vivo toxicity. Mice (female BALB/c, 6-8 weeks, 18-22 g) were divided into control and test groups with 5 mice per group. In the test groups, 100 µL of the gel solution (after immediate mixing of both the components with or without antibiotics) was injected subcutaneously above the thoracic midline (dorsal). In control groups, 100 µL of saline was injected similarly. After 3 and 7 days, mice were sacrificed; tissue surrounding the gel was collected, fixed in 10% formalin and analyzed for histopathological studies via hematoxylin and eosin staining (Supporting Information).30

2.11 Subcutaneous infection of MRSA. Female BALB/c mice (6 to 7 weeks old, 18-21g) were used for the experiment. The mice were first rendered neutropenic (∼100 neutrophils/mL) by injecting cyclophosphamide, i.p. (first dose at 150 mg/kg and then second dose at 100 mg/kg after 3 days of the first dose). Fur above the thorasic midline of each animal was clipped. Then hydrogel (2.5 wt% PDA with 0.3 wt% vancomycin and 2.0 wt% HTCC, 100 µL) was injected subcutaneously. Then MRSA (∼107 CFU/mL, 40 µL) was injected directly into the gel. In another group of mice, bacteria were injected at a distal site


Page 10 of 36

Page 11 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

(1.5-2.0 cm) from the gel. In another group, bacteria (100 µL saline + 40 µL ∼107 CFU/mL MRSA) were injected subcutaneously below the thorasic midline. After 3 days, the animals were sacrificed and surrounding tissues were collected. Tissue samples were then homogenized, and used for cell counting by plating the homogenized solution on nutrient agar plate followed by 10-fold serial dilution. The MRSA count was then expressed as log CFU/g of tissue and expressed as mean ± standard error of mean. A small section of the skin tissue from the injection site was also fixed in 10% formalin to study the histological responses.

3. Results and Discussion 3.1 Synthesis and characterization of the hydrogels. Hydrogels with innate bioadhesive and antibacterial properties were prepared using HTCC (degree of quaternization 44%, % of free amine groups 41% and degree of acetylation 15%) (Figure 1a) and PDA (dialdehyde functionality ∼50%) (Figure 1b) via dual barrel syringe.30 It was shown that HTCC with its free amine groups reacted with the aldehyde groups of PDA leading extensive cross-linking and hence hydrogelation. The bioadhesive polymer PDA was obtained via periodate oxidation of dextran (molecular weight ∼40 kDa) and antibacterial polymer HTCC was synthesized

via

quaternization

of

chitosan

(molecular

weight

15

kDa)

with

glycidyltrimethylammonium chloride (Scheme S1 and S2).35,36 Finally, antibiotic-loaded gels were prepared by mixing phosphate buffer (pH ∼7.2) solution of PDA and vancomycin (Figure 1c) with the aqueous solution of HTCC (Figure 1d). At first, vancomycin was dissolved in phosphate buffer at 1 mg/mL, 6 mg/mL and 12 mg/mL respectively. Solid PDA was then added to the each antibiotic containing buffer solutions individually to obtain 50 mg/mL of PDA. After 1 h, 40 mg/mL of HTCC dissolved in Millipore water was added to the polymer-antibiotic solutions in equal volume via dual barrel syringe which led to the


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

formation of hydrogels within 10-15 seconds (Table S1). Thus three different vancomycin (V) containing injectable hydrogels (IH) named as IHV-1 (2.5 wt% PDA with 0.05 wt% vancomycin and 2.0 wt% HTCC), IHV-2 (2.5 wt% PDA with 0.3 wt% vancomycin and 2.0 wt% HTCC) and IHV-3 (2.5 wt% PDA with 0.6 wt% vancomycin and 2.0 wt% HTCC) were obtained. Hydrogel without any vancomycin IHV-0 (2.5 wt% PDA and 2.0 wt% HTCC) was also prepared. The viscoelastic properties of the hydrogels were studied by determining the elastic modulus (G′) and loss modulus (G′′) using pre-formed gels via oscillatory rheometer as a function of frequency.37 Notably, G′ values of all the vancomycin-loaded hydrogels (IHV-1, IHV-2 and IHV-3) were found to be closure to that of the gel without vancomycin (IHV-0) (Figure S1). While the IHV-0 showed G′ value of 830±120 Pa, the elastic modulus values of IHV-1, IHV-2 and IHV-3 were 847±87 Pa, 887±141 Pa and 849±110 Pa respectively (Table S1). The above facts thus indicated that vancomycin loading has negligible effect of the mechanical stiffness of the gels. Notably, G′ values were found to be much higher than the G′′ values over the entire frequency range (1-100 rad/s) for all the hydrogel formulations which indicated strong gel formation (Figure S1). The surface as well as cross-sectional morphologies of the gels was observed by scanning electron microscopy after freeze-drying the gel disks followed by gold-sputtering. The surface morphologies of all the hydrogels showed a thin polymer layer which is probably due to the collapse of surface pores during the freeze-drying process (Figure 2a). However, the cross-sectional morphologies of all the gels showed characteristic sponge-like interconnected and porous structures with a number of irregular lamellar features (Figure 2b). FT-IR spectroscopy was employed to identify the functional groups within the gels. Though PDA showed a peak at 1640 cm−1 in the IR spectra, the peak at 1650 cm−1 was assumed to be imine bond (C=N stretching) formed between vancomycin or HTCC and PDA (Figure 3a,b). Also, the presence of amide II peak


Page 12 of 36

Page 13 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

(N−H stretching) at 1586 cm−1 was clearly evident from the spectra that originated from vancomycin amide group. Further, the IR spectra showed the presence of aromatic ring stretch (C=C stretching) at 1479 cm−1 thus confirming successful encapsulation of antibiotic within the hydrogel matrix (Figure 3a,b).

3.2 Determination of vancomycin conjugation. As vancomycin contains free primary amine group, it is therefore expected that this antibiotic will form reversible imine bonds with the aldehyde groups of PDA leading to covalent encapsulation into the gel matrix. To evaluate the extent of covalent coupling of vancomycin with PDA, the polymer-antibiotic mixtures after 1 h were dialysed to remove non-conjugated antibiotic if there was any and then freeze dried. The covalent coupling of the antibiotic with PDA was confirmed by FT-IR, 1

H NMR and quantified by elemental analysis. Though the peak of amide I (C=O stretching)

from vancomycin and the imine bond (C=N stretching) formed between vancomycin and PDA came at around 1644 cm−1, the presence of amide II peak at 1583 cm−1 from vancomycin was clearly evident in IR spectra of the freeze-dried PDA-antibiotic mixtures (Figure 3c,d). Further, the spectra showed the presence of aromatic ring stretch (C=C stretching) at 1506 cm−1 which were absent in the non-conjugated PDA and originated from the coupled vancomycin (for vancomycin the same peak was observed at 1507 cm−1). 1H NMR spectra of the PDA-antibiotic samples showed aromatic protons in the regions of 7.2 to 7.8 ppm which indicated the presence of benzene ring of vancomycin along with the other protons of either vancomycin or PDA in the region of 2.5-6.5 ppm (Figure S2-S5). Finally, the % of antibiotic coupling was quantified from the elemental analysis of PDA-antibiotic samples. The analyses showed that the nitrogen contents in vancomycinconjugated PDA were 0.18%, 0.79% and 1.54% of the mass, which indicated 100% coupling for PDA-antibiotic conjugate with 0.05 wt% vancomycin, (stoichiometrically nitrogen


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

content for 100% conjugation would be 0.17%); ∼85% coupling for PDA-antibiotic conjugate with 0.3 wt% vancomycin (stoichiometrically nitrogen content for 100% conjugation would be 0.93%); and 91% coupling for PDA-antibiotic conjugate with 0.6 wt% vancomycin (stoichiometrically nitrogen content for 100% conjugation would be 1.68%). The above results thus suggested that vancomycin is primarily bonded via covalent imine bond in all the hydrogel formulations.

3.3 In-vitro antibacterial activity. Next antibacterial efficacy of the hydrogels was evaluated by exposing the gel’s surface to bacterial suspension. First the gels (IHV-0, IHV-1, IHV-2 and IHV-3, 100 µL) were prepared in the wells of a 96-well plate and then challenged with bacteria (150 µL of 1.7 × 105 CFU/mL drug-sensitive Staphylococcus aureus). Cell viability was then determined by plating the suspension on suitable agar plate after 6 h of treatment and then counting the colonies. Blank wells without any gels and hydrogel without any antibiotic (IHV-0) were used as controls. Interestingly, all the gels significantly reduced the bacterial viability. While the blank wells showed 9.5 ± 0.9 log CFU/mL S. aureus, IHV-0 showed 3.4±0.5 log CFU/mL bacteria after 6 h of incubation. Interestingly, gels with vancomycin (IHV-1, IHV-2 and IHV-3) showed no survival of bacteria thus demonstrating the superior efficacy in killing S. aureus (Figure 4a). Similar results were obtained for the drug-resistant bacteria when the gels were challenged with MRSA (150 µL, 1.2 × 104 CFU/mL). While the blank wells were shown to have 6.8±0.7 log CFU/mL MRSA after 6 h, IHV-1, IHV-2 and IHV-3 showed complete killing of MRSA (Figure 4b). Superior efficacy of the vancomycin-containing hydrogels was further established by challenging the gel’s surface with higher amount of bacteria. Interestingly while the blank wells showed 10.2 ± 1.1 log CFU/mL of bacteria after 6 h, gels with no or less antibiotic such as IHV-0 and IHV-1 showed 3.8 ± 0.8 log CFU/mL and 2.4 ± 0.4 log CFU/mL of bacteria when incubated with an


Page 14 of 36

Page 15 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

initial amount of 1.67 × 107 CFU/mL of S. aureus. However, no bacteria were observed for the gels with higher amount of antibiotic, e.g., IHV-2 and IHV-3 (Figure 4c). Not only against drug-sensitive bacteria, antibiotic-loaded gels showed remarkably higher activity than gels with no antibiotic. For example, for an initial amount of 1.1 × 106 CFU/mL of MRSA, while the blank wells showed 8.7 ± 1.1 log CFU/mL of MRSA after 6 h, IHV-0 and IHV-1 showed 2.8 ± 0.4 log CFU/mL and 2.3 ± 0.7 log CFU/mL of bacteria. IHV-2 and IHV-3, on the other hand, showed no bacteria thus indicating complete eradication of MRSA (Figure 4d). The above results thereby suggested that the antibiotic encapsulated gels are acting more effectively possibly by killing bacteria upon contact as well as by releasing vancomycin in the media. The above results also indicated that gel with an optimum amount of antibiotic (as in the case of IHV-2 which contains 0.3 wt% of antibiotic) is required for utmost efficacy.

3.4 Released based activity (Zone of inhibition). In order to establish that the gels released antibiotic into the surroundings, zone of inhibition (ZOI) experiment was performed. This was done by preparing the gel on a suitable agar plate after removing a circular portion of agar, spreading MRSA (1 mL of ∼108 CFU/mL) on the plate and then allowing to form bacterial lawns for about 24 h at 37 ˚C. As expected IHV-0 did not show any zone of clearance though it showed no colonies on the gel’s surface thus inactivate bacteria only upon contact (Figure 5a). IHV-1, IHV-2 and IHV-3, on the other hand, displayed significant zone of inhibition against MRSA lawns grown on the agar plate thereby indicating the diffusion of vancomycin to the surroundings which inactivated bacteria in the respective areas (Figure 5bd). Furthermore, IHV-3 with highest amount of encapsulated antibiotic showed maximum zone of inhibition while IHV-1 with lowest amount of encapsulated drug showed minimum inhibition zone.


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

In order to assess further that the cationic gel without any antibiotic killed bacteria only upon contact whereas gels with antibiotic kill bacteria by both release and contact active mechanism, the gels were prepared within the separate inserts of a transwell cell culture plate.29,38 The inserts were then placed in the wells which were spatially separated from the bacteria proliferating below in the wells of a tissue culture plate. Like the control wells, substantial bacterial growth was observed in the wells with inserts containing IHV-0 after 24 h. If there was any release of HTCC from IHV-0, the bacterial growth should have been inhibited. The above results thus suggested that IHV-0 is capable of reducing bacterial count only on contact (Figure 5e,f). Interestingly, wells with inserts that contained IHV-1, IHV-2 and IHV-3 showed no growth of bacteria thus indicated that these gels released vancomycin in the bottom solution leading to bacterial inhibition (Figure 5e,f).

3.5 Extended release of antibiotic and long lasting antibacterial activity. As most of the antibiotic was primarily incorporated via reversible covalent imine bond (100% for IHV-1 and more than 85% for IHV-2 and IHV-3) into the hydrogel matrix, it is expected that the gels will release the antibiotic over a period of time and hence will be able to display long lasting antibacterial activity. We therefore studied the antibiotic release kinetics by taking all three hydrogels (400 µL) wherein IHV-1, IHV-2 and IHV-3 contained 200 µg, 1200 µg and 2400 µg of the antibiotic respectively. Since the infection sites are commonly acidic in nature, the release kinetic was studied at three different pHs starting from neutral to acidic (pH 7.2, 6.2 and 5.5 respectively). First, 1 mL of buffer with specific pH was added to the eppendorp tubes containing the gels and incubated for 24 h. Then, the buffer solutions were collected and fresh buffer was added. Finally, the amount vancomycin released was quantified by UV-visible spectroscopy (at 281 nm absorption of vancomycin).


Page 16 of 36

Page 17 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Notably, gels were shown to release the antibiotic continuously over 14 days as tested in all three pH (Figure 6). Interestingly, release of vancomycin was found to be dependent on the initial amount of loading (Figure 6a-c). Further, the release kinetics was also found to be dependent on pH of the buffer. At higher (pH 7.2), slightly higher amount of vancomycin was found to be released. For example, while IHV-2 showed ∼49-50% release at pH 5.5 and 6.2, 62% release was observed at pH 7.2 after 14 days (Figure 6d-f). It should be mentioned that after 11 days, the UV-absorption spectra of the collected buffer solutions showed the presence of a weak absorption peak at 290-300 nm in addition to a peak at 281 nm at lower pH (pH 5.5 or 6.2). This indicated that a minor amount of PDA-van conjugates with imine bonds got released from the gels along with the free antibiotics. Thus the studies were conducted till 14 days at all three pHs. It should also be mentioned that the IHV-2 and IHV-3 gels released slightly higher proportion of antibiotic in the first 1-2 days possibly by combined release of the covalently bonded vancomycin as well as diffusion of non-covalently bonded antibiotic (Figure 6). However, the rate of release was found to be almost linear for all three formulations possibly due to the drug release being mostly controlled by the opening of the covalent imine bonds. In general, the above results indicated that an extended release of the drug was achievable by encapsulating antibiotics in the hydrogel network. Interestingly, gels with higher amount of vancomycin (IHV-2 or IHV-3) were shown to release the antibiotic till 40 days (at pH 7.2) which indicated the effectiveness of the matrix in controlling the release behavior of the antibiotic (for IHV-1 it was difficult to detect the vancomycin as the peak intensity at 281 nm was found to be very poor after 12 days). A drug-carrier must retain the bioactivity of the encapsulated drug during and/or after fabrication. Herein we tested the antibacterial activity of the released vancomycin collected in nutrient media for one of the most active formulations (IHV-2). Notably, the release media inactivated MRSA completely till 14 days as tested (Figure S6). Further, the released


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

vancomycin from the gels showed same retention time as the commercial vancomycin in high-performance liquid chromatography (HPLC) (Figure S7). These results thus portrayed the utilities of the vancomycin-loaded hydrogels as dual action drug-carrier with effective and sustained release properties.

3.6 Biocompatibility. It is known that the cationic polymers or hydrogels interact with the mostly negatively charged bacterial cell membrane leading cellular inactivation.39,40 However unlike bacterial cell membranes, mammalian cell membranes are mostly composed of zwitterionic lipids thus relatively less susceptible towards quaternary ammonium moiety. Though the differences in bacterial and mammalian cell membrane are significant, cationic hydrogels with substantial amount of antibiotic might also cause toxicity towards mammalian cells. We therefore studied the compatibility of the gels in-vitro against human red blood cells (hRBC) and in-vivo via subcutaneous implantation in mice.41 Hemocompatibility of the gels was evaluated by exposing the gel’s surfaces with hRBC and finding out the percentage of hemolysis occurred with respect to a toxic surfactant triton-X (TX-100). All the vancomycin-loaded hydrogels (IHV-1, IHV-2 and IHV-3) showed negligible hemolysis like the gel without any antibiotic (IHV-0). Only 2-3% hemolysis was observed for all the hydrogel formulations (Figure S8). This implied that the gels were compatible against human erythrocytes. In order to have visual insight, blood cells were also imaged via optical microscopy after exposing them to the gel’s surface. Notably, treated cells were found to have healthy and round morphology typical of normal blood cells as observed in the case of control (non-treated hRBC). In contrast, TX-100 treated samples showed complete killing of cells as no RBCs were observed under microscope (Figure 7a-f). The biocompatibility of the hydrogels was then evaluated in-vivo by injecting one of the most potent antibiotic-loaded gels (100 µL, IHV-2) subcutaneously in mice. After 3 days


Page 18 of 36

Page 19 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

and 7 days of post-implantation the histopathological responses in the surrounding tissue was recorded via haematoxylin and eosin staining. Interestingly, the tissue surrounding the gel showed negligible inflammation and normal architecture of dermis, epidermis and subcutaneous tissues like the saline treated tissue samples (Figure S9). The above results therefore suggested that gels were indeed non-toxic towards mammalian cells.

3.7 In-vivo activity (Subcutaneous model of MRSA infection). The antibacterial efficacy of the antibiotic loaded gels was also established in-vivo via subcutaneous infection model in mice. Further, to prove that the gel is able to deliver antibiotics locally at the target site, infection at distal site (far from the gel) and subsequent removal of bacteria by the implanted hydrogel was also performed.22 First, IHV-2 (100 µL) was injected subcutaneously in mice that were already rendered neutropenic. In one group (n = 5) bacteria (40 µL of ∼107 CFU/mL MRSA) were then directly injected into the gel. In another group (n = 5) bacteria were injected at a distal site such that only the released antibiotics can reach the infected area. Bacteria were also injected without the gel and gel without any antibiotic (IHV-0) and were used as controls. Once the infection was clinically evident in the control mice (after 72 h), both the control and experimental mice were killed and infection sites were imaged. While significant amount of pus formation was noticed when MRSA was injected in mice, no pus formation was observed when bacteria were injected into the gel (Figure S10). Interestingly, no pus formation was observed even when the bacteria were injected at a distal site from the gel thereby suggesting that the antibiotic got released from the gel and reduced the viable bacteria. The number of viable bacteria in the mice tissues was also determined. First, the infected tissue were collected and subsequently homogenised. Finally, the tissue lysate was then plated on suitable agar plate and enumerated for bacterial count. When bacteria were


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

injected directly onto the gel IHV-2, tissue surrounding IHV-2 showed 6.1 log less MRSA (99.9999% reduction) as compared to the non-treated tissue sample (while the non-treated tissue showed ∼9.9 log CFU/g of MRSA, the gel treated tissue sample showed 3.8 log CFU/g of MRSA) (Figure 8a). Most importantly, 5.8 log (99.999%) reduction of MRSA was observed for IHV-2 gel when bacteria were injected at a distal site (the gel and infection site were separated by ∼1.5-2.0 cm) (Figure 8a). This is possible due to the gradual release of the antibiotic in the surroundings over time thus leading to the inhibition/clearance of bacterial growth even when the bacteria were injected far from the gel. To establish that it is the released antibiotics which reduced MRSA count, we also injected bacteria at a similar distance from the gel that contain no antibiotic (IHV-0), almost same amount of MRSA like the control case (∼9.6 log CFU/g) was observed. The efficacy of the gel was further established by histopathology examination of both treated and untreated tissue samples. While the control tissue samples showed severe infiltration of inflammatory cells mostly neutrophils and mononuclear cells in the subcutaneous tissues (arrow) with congestion of blood vessels (inset) (Figure 8b), tissue surrounding the antibiotic loaded gel showed normal morphology with minimal inflammation at the epidermis, dermis and skin tissue upon injection of MRSA both into the gel and far from the gel (Figure 8c,d). Collectively, the above results indicated that the vancomycin containing gel was able to reduce infection in the surrounding tissues and prevent the spreading of infections.

4. Conclusion In summary, a highly efficient dual function vancomycin-loaded injectable hydrogel capable of delivering the antibiotic in the target sites was developed. The antibiotic was encapsulated into the hydrogel matrix made up of polydextran aldehyde and N-(2-hydroxypropyl)-3-


Page 20 of 36

Page 21 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

trimethylammonium chitosan chloride mostly via imine bonds which facilitated its local delivery in pH dependent manner. Further, the hydrogels being inherently antibacterial synergized with the antibiotic and killed bacteria via both contact- and released- active mechanisms. The gels released vancomycin over a significantly extended period of time in a highly controlled manner via the formation and opening of imine bonds and displayed potent long-lasting antibacterial activity. In animal model study, the vancomycin-containing gel killed >99.999% MRSA when introduced both into the gel and at distal site far from the gel. One of the most active formulations (PDA 2.5 wt%, HTCC 2.0% with 0.3 wt% vancomycin) showed no toxicity towards human red blood cells and to the surrounding tissue when injected subcutaneously in mice. The vancomycin-loaded injectable hydrogel developed herein thus could be potentially used to deliver antibiotics locally and as a non-invasive antiinfective material to treat infections in relatively less vascular or avascular tissue infections.

Supporting Information The Supporting Information is available free of charge on the ACS Publications website. Synthesis of polymers, characterization procedure and data of hydrogels, figures showing invitro antibacterial and haemolytic activities data, figure showing in-vivo activity data.

Acknowledgement We thank Prof. C. N. R. Rao, FRS (JNCASR) for his constant support and encouragement. J. Hoque thanks JNCASR for funding. B. Bhattacharjee thanks Council of Scientific and Industrial Research (CSIR), Govt. of India, for Junior Research Fellowship (JRF).


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Author Information Corresponding author *E-mail: [email protected]; Ph: +91-080-2208-2716

Notes These authors declare no competing financial interest.

References 1. Darley, E. S.; MacGowan, A. P. Antibiotic Treatment of Gram-Positive Bone and Joint Infections. J. Antimicrob. Chemother. 2004, 53, 928-935. 2. Smith, R. L.; Schurman, D. J.; Kajiyama, G.; Mell, M.; Gilkerson, E. The Effect of Antibiotics on the Destruction of Cartilage In Experimental Infectious Arthritis. J. Bone Joint Surg. Am. 1987, 69, 1063-1068. 3. Owens, C. D.; Stoessel, K. Surgical Site Infections: Epidemiology, Microbiology and Prevention. J. Hosp. Infect. 2008, 70, 3-10. 4. Campoccia, D.; Montanaro, L.; Arciola, C. R. The Significance of Infection Related To Orthopedic Devices and Issues of Antibiotic Resistance. Biomaterials 2006, 27, 2331-2339. 5. Reichman, D. E.; Greenberg, J. A. Reducing Surgical Site Infections: A Review. Rev. Obstet. Gynecol. 2009, 2, 212-221. 6. Hall-Stoodley, L.; Costerton, J. W.; Stoodley, P. Bacterial Biofilms: From the Natural Environment To Infectious Diseases. Nat. Rev. Microbiol. 2004, 2, 95-108. 7. Howell-Jones, R. S.; Wilson, M. J.; Hill, K. E.; Howard, A. J.; Price, P. E.; Thomas, D. W. A Review of The Microbiology, Antibiotic Usage and Resistance In Chronic Skin Wounds. J. Antimicrob. Chemother. 2005, 55, 143-149. 8. Stengel, D.; Bauwens, K.; Sehouli, J.; Ekkernkamp, A.; Porzsolt, F. Systematic Review and Meta-Analysis of Antibiotic Therapy for Bone and Joint Infections. Lancet. Infect. Dis. 2001, 1, 175-188.


Page 22 of 36

Page 23 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

9. Pritchard, E. M.; Valentin, T.; Panilaitis, B.; Omenetto, F.; Kaplan, D. L. AntibioticReleasing Silk Biomaterials for Infection Prevention and Treatment. Adv. Funct. Mater. 2013, 23, 854-861. 10. Conejero-Muriel, C.; Gavira, J. A.; Pineda-Molina, E.; Belsom, A.; Bradley, M.; Moral, M.; de Dios García-López Durán, J.; González, A. L.; Díaz-Mochón, J. J.; ContrerasMontoya, R.; Martínez-Peragón, A.; Cuerva, J. M.; de Cienfuegos, L. A. Influence of the Chirality of Short Peptide Supramolecular Hydrogels in Protein Crystallogenesis. Chem. Commun. 2015, 51, 3862-3865. 11. Shiha, Y.-R.; Kanga, H.; Rao, V.; Chiub, Y.-J.; Kwona, S. K.; Varghese, S. In Vivo Engineering of Bone Tissues with Hematopoietic Functions and Mixed Chimerism. Proc. Natl. Acad. Sci. USA 2017, 114, 5419-5424. 12. Hoque, J.; Haldar, J. Direct Synthesis of Dextran-Based Antibacterial Hydrogels for Extended Release of Biocides and Eradication of Topical Biofilms. ACS Appl. Mater. Interfaces 2017, 9, 15975-15985. 13. Lakes, A. L.; Peyyala, R.; Ebersole, J. L.; Puleo, D. A.; Hilt, J. Z.; Dziubla, T. D. Synthesis and Characterization of an Antibacterial Hydrogel Containing Covalently Bound Vancomycin. Biomacromolecules 2014, 15, 3009-3018. 14. Nadithe, V.; Liu, R.; Killinger, B. A.; Movassaghian, S.; Kim, N. H.; Moszczynska, A. B.; Masters, K. S.; Gellman, S. H.; Merkel, O. M. Screening Nylon-3 Polymers, a New Class of Cationic Amphiphiles, for siRNA Delivery. Mol. Pharmaceutics 2015, 12, 362-374. 15. Custódio, C. A.; Reis, R. L.; Mano, J. F. Photo-Cross-Linked Laminarin-Based Hydrogels for Biomedical Applications. Biomacromolecules 2016, 17, 1602-1609. 16. Ghobril, C.; Charoen, K.; Rodriguez, E. K.; Nazarian, A.; Grinstaff, M. W. A Dendritic Thioester Hydrogel Based on Thiol-Thioester Exchange as a Dissolvable Sealant System For Wound Closure. Angew. Chem. Int. Ed. 2013, 52, 14070-14074.


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

17. Dong, R. N.; Zhao, X.; Guo, B. L.; Ma, P. X. Self-Healing Conductive Injectable Hydrogels with Antibacterial Activity as Cell Delivery Carrier for Cardiac Cell Therapy. ACS Appl. Mater. Interfaces 2016, 8, 17138-17150. 18. Lee, Y.; Choi, K. H.; Park, K. M.; Lee, J. M.; Park, B. J.; Park, K. D. In Situ Forming and H2O2-Releasing Hydrogels for Treatment of Drug-Resistant Bacterial Infections. ACS Appl. Mater. Interfaces 2017, 9, 16890-16899. 19. Nimal, T. R.; Baranwal, G.; Bavya, M. C.; Biswas, R.; Jayakumar, R. Antistaphylococcal Activity of Injectable Nano Tigecycline/Chitosan-PRP Composite Hydrogel Using Drosophila melanogaster Model for Infectious Wounds. ACS Appl. Mater. Interfaces 2016, 8, 22074-22083. 20. Nejad, A. G.; Park, C. H.; Kim, C. S. In Situ Synthesis of Antimicrobial Silver Nanoparticles within Antifouling Zwitterionic Hydrogels by Catecholic Redox Chemistry for Wound Healing Application. Biomacromolecules 2016, 17, 1213-1223. 21. Ryu, J. H.; Lee, Y.; Kong, W. H.; Kim, T. G.; Park, T. G.; Lee, H. CatecholFunctionalized Chitosan/Pluronic Hydrogels For Tissue Adhesives and Hemostatic Materials. Biomacromolecules 2011, 12, 2653-2659. 22. Li, Y.; Fukushima, K.; Coady, D. J.; Engler, A. C.; Liu, S.; Huang, Y.; Cho, J. S.; Guo, Y.; Miller, L. S.; Tan, J. P.; Ee, P. L.; Fan, W.; Yang, Y. Y.; Hedrick, J. L. Broad-Spectrum Antimicrobial and Biofilm-Disrupting Hydrogels: Stereocomplex-Driven Supramolecular Assemblies. Angew. Chem. Int. Ed. 2013, 52, 674-678. 23. Vulic, K.; Shoichet, M. S., Tunable Growth Factor Delivery From Injectable Hydrogels For Tissue Engineering. J. Am. Chem. Soc. 2012, 134, 882-885. 24. Lee, H.; Lee, B. P.; Messersmith, P. B. A Reversible Wet/Dry Adhesive Inspired By Mussels and Geckos. Nature 2007, 448, 338-341.


Page 24 of 36

Page 25 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

25. Hudson, S. P.; Langer, R.; Fink, G. R.; Kohane, D. S. Injectable In Situ Cross-Linking Hydrogels for Local Antifungal Therapy. Biomaterials 2010, 31, 1444-1452. 26. Guo, J.; Wang, W.; Hu, J.; Xie, D.; Gerhard, E.; Nisic, M.; Shan, D.; Qian, G.; Zheng, S.; Yang, J. Synthesis and Characterization of Anti-Bacterial and Anti-Fungal Citrate-Based Mussel-Inspired Bioadhesives. Biomaterials 2016, 85, 204-217. 27. Zhang, Y.; Zhang, J.; Chen, M.; Gong, H.; Thamphiwatana, S.; Eckmann, L.; Gao, W.; Zhang, L. A Bioadhesive Nanoparticle-Hydrogel Hybrid System for Localized Antimicrobial Drug Delivery. ACS Appl. Mater. Interfaces 2016, 8, 18367-18374. 28. Stefanov, I.; Rafael, S. P.; Hoyo, J.; Cailloux, J.; Pérez, O. O. S.; Caballero, D. H.; Tzanov, T. Multifunctional Enzymatically Generated Hydrogels for Chronic Wound Application. Biomacromolecules 2017, 18, 1544-1555. 29. Giano, M. C.; Ibrahim, Z.; Medina, S. H.; Sarhane, K. A.; Christensen, J. M.; Yamada, Y.; Brandacher, G.; Schneider, J. P. Injectable Bioadhesive Hydrogels With Innate Antibacterial Properties. Nat Commun 2014, 5, 4095. 30. Hoque, J.; Prakash, R. G.; Paramanandham, K.; Shome, B. R.; Haldar, J. Biocompatible Injectable Hydrogel with Potent Wound Healing and Antibacterial Properties. Mol Pharmaceutics 2017, 14, 1218-1230. 31. Zhao, X.; Wu, H.; Guo, B. L.; Dong, R. N.; Qiu, Y. S.; Ma, P. X. Antibacterial AntiOxidant Electroactive Injectable Hydrogel as Self-Healing Wound Dressing With Hemostasis and Adhesiveness for Cutaneous Wound Healing. Biomaterials 2017, 122, 34-47. 32. Guo, J. S.; Kim, G. B.; Shan, D. Y.; Kim, J. P.; Hu, J. Q.; Wang, W.; Hamad, F. G.; Qian, G.; Rizk, E. B.; Yang, J. Click Chemistry Improved Wet Adhesion Strength of MusselInspired Citrate-Based Antimicrobial Bioadhesives. Biomaterials 2017, 112, 275-286.


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 26 of 36

33. Yarlagadda, V.; Samaddar, S.; Paramanandham, K.; Shome, B. R.; Haldar, J. Membrane Disruption and Enhanced Inhibition of Cell-Wall Biosynthesis: A Synergistic Approach to Tackle Vancomycin-Resistant Bacteria. Angew. Chem. Int. Ed. 2015, 54, 13644-13649. 34. Yarlagadda, V.; Akkapeddi, P.; Manjunath, G. B.; Haldar, J. Membrane Active Vancomycin Analogues: A Strategy to Combat Bacterial Resistance. J. Med. Chem. 2014, 57, 4558-4568. 35. Hoque, J.; Adhikary, U.; Yadav, V.; Samaddar, S.; Konai, M. M.; Prakash, R. G.; Pararnanandham, K.; Shome, B. R.; Sanyal, K.; Haldar, J. Chitosan Derivatives Active against Multidrug-Resistant Bacteria and Pathogenic Fungi: In Vivo Evaluation as Topical Antimicrobials. Mol Pharmaceutics 2016, 13, 3578-3589. 36. Maia, J.; Ferreira, L.; Carvalho, R.; Ramos, M. A.; Gil, M. H. Synthesis and Characterization of New Injectable and Degradable Dextran-Based Hydrogels. Polymer 2005, 46, 9604-9614. 37. Rosales, A. M.; Mabry, K. M.; Nehls, E. M.; Anseth, K. S. Photoresponsive Elastic Properties

of

Azobenzene-Containing

Poly(ethylene-glycol)-based

Hydrogels.

Biomacromolecules 2015, 16, 798-806. 38. Pappas, H. C.; Phan, S.; Yoon, S.; Edens, L. E.; Meng, X. L.; Schanze, K. S.; Whitten, D. G.; Keller, D. J. Self-Sterilizing, Self-Cleaning Mixed Polymeric Multifunctional Antimicrobial Surfaces. ACS Appl. Mater. Interfaces 2015, 7, 27632-27638. 39. Li, P.; Poon, Y. F.; Li, W.; Zhu, H. Y.; Yeap, S. H.; Cao, Y.; Qi, X.; Zhou, C.; Lamrani, M.; Beuerman, R. W.; Kang, E. T.; Mu, Y.; Li, C. M.; Chang, M. W.; Leong, S. S.; ChanPark, M. B. A Polycationic Antimicrobial and Biocompatible Hydrogel With Microbe Membrane Suctioning Ability. Nat. Mater. 2011, 10, 149-156.


Page 27 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

40. Hoque, J.; Akkapeddi, P.; Ghosh, C.; Uppu, D. S. S. M.; Haldar, J. A Biodegradable Polycationic Paint that Kills Bacteria in Vitro and in Vivo. ACS Appl. Mater. Interfaces 2016, 8, 29298-29309. 41. Lee, C.; Shin, J.; Lee, J. S.; Byun, E.; Ryu, J. H.; Um, S. H.; Kim, D.-I.; Lee, H.; Cho, S.W. Bioinspired, Calcium-Free Alginate Hydrogels with Tunable Physical and Mechanical Properties and Improved Biocompatibility. Biomacromolecules 2013, 14, 2004-2013.


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 1. Structures of hydrogel precursors and schematic representation of the antibiotic loaded hydrogels. (a) Structure of HTCC; (b) structure of PDA; (c) structure of vancomycin. (d) Schematic representation of the antibiotic loaded hydrogels showing both covalent and non-covalent encapsulation. Physical characterization of the vancomycin loaded gels.


Page 28 of 36

Page 29 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 2. Morphology of the antibiotic loaded hydrogels: (a) surface morphologies and (b) cross-sectional morphologies of hydrogels.


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 3. FT-IR spectra of PDA, vancomycin and all four hydrogel formulations in the dry state: (a) full spectra; (b) spectra from 2000-1000 cm−1 respectively. IR spectra of only PDA, vancomycin and all three PDA-vancomycin conjugates: (a) full spectra; (b) spectra from 2000-1000 cm−1 respectively.


Page 30 of 36

Page 31 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 4. Antibacterial activity of the hydrogels. Bacterial count after 6 h when 150 µL of the pathogen was challenged against the hydrogel’s surface: (a) S. aureus count with an initial amount 1.7 × 105 CFU/mL (150 µL); (b) MRSA count with an initial amount 1.2 × 104 CFU/mL; (c) S. aureus count with an initial amount 1.67 × 107 CFU/mL and (d) MRSA count with an initial amount 1.1 × 106 CFU/mL. Stars represent less than 50 CFU/mL.


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 5. Inhibition of bacterial lawn growth induced by releasing the antibiotic (vancomycin) containing hydrogels. Each plate has a confluent lawn of MRSA cells where the antibiotic diffused out from the central hydrogel disc and killed the surrounding bacteria leaving a clear zone. The hydrogels consisted of PDA and HTCC containing (a) 2.5 wt% PDA with 0 wt% vancomycin and 2.0 wt% HTCC (IHV-0); (b) 2.5 wt% PDA with 0.05 wt% vancomycin and 2.0 wt% HTCC (IHV-1); (c) 2.5 wt% PDA with 0.3 wt% vancomycin and 2.0 wt% HTCC (IHV-2) and (d) 2.5 wt% PDA with 0.6 wt% vancomycin and 2.0 wt% HTCC (IHV-3). Antibacterial activity with the released vancomycin from the gels against (e) S. aureus and (f) MRSA respectively.


Page 32 of 36

Page 33 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 6. Antibiotic release from the vancomycin-containing hydrogels. The amount of antibiotic released at different time interval from (a) IHV-1; (b) IHV-2 and (c) IHV-3 respectively. IHV-1, IHV-2 and IHV-3 contained an initial 200 µg, 1200 µg and 2400 µg of vancomycin and were used for release kinetics by adding 1 mL of buffer solution at varying pH and replacing the old buffer with fresh one after every 24 h. The amount antibiotic content in the solution was then determined by UV-visible absorption spectroscopy. Cumulative release of vancomycin from (d) IHV-1; (e) IHV-2 and (f) IHV-3 respectively.


Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 7. Biocompatibility of the hydrogels. Hemolytic activity of the gels as a function of increasing antibiotic content and the controls (untreated and TX-100). Optical micrograph images of hRBC collected from the surface for the hydrogels or controls: (a) control; (b) IHV-0; (c) IHV-1; (d) IHV-2; (e) IHV-3 and (f) TX. Scale bar 50 µm.


Page 34 of 36

Page 35 of 36

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 8. In-vivo activity of the hydrogels. Evaluation of antibacterial activity upon injection of MRSA subcutaneously in mice: (a) MRSA count after 72 h of infection at different conditions; p values (*) are 0.002,

Dual Function Injectable Hydrogel for Controlled Release of Antibiotic

Recommend Documents